Compare Novo Nordisk A/S (NVO) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Roblox Corp — how do they compare? Novo Nordisk A/S trades at $46.43 (market cap $207.85B), while Roblox Corp trades at $35.65 (market cap $25.87B). The key difference: Novo Nordisk A/S is far larger — about 8× Roblox Corp's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| NVO | RBLX | |
|---|---|---|
Market Cap | $207.85B | $25.87B |
Sector | Health | Media |
52-Week High | $63.98 | $141.56 |
52-Week Low | $35.29 | $35.60 |
Enterprise Value | $222.55B | $24.70B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
RBLX trades at $35.76, down 3.48% in the last session, with a bearish technical outlook from moving averages. The company reported revenue growth to $4.89 billion in 2025 but remains unprofitable, with a net loss of $1.07 billion. Analyst consensus is mixed, with a $45.67 price target, while recent news highlights multiple class-action lawsuits filed against the company.
The outlook is clouded by persistent losses and legal challenges, though revenue growth and strong operating cash flow of $1.80 billion offer some fundamental support. Risks include profitability challenges and litigation, but the stock may appeal to growth-oriented investors if execution improves and losses narrow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
